



UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/705,173 ✓	11/06/2003	Xi Chen	11134-013-999	4030
20583	7590	08/10/2006	EXAMINER	
JONES DAY 222 EAST 41ST ST NEW YORK, NY 10017			AULAKH, CHARANJIT	
			ART UNIT	PAPER NUMBER
			1625	

DATE MAILED: 08/10/2006

Amendment due 11/10/06
Interview Summary 9/10/06

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary	Application No. 10/705,173	Applicant(s) CHEN ET AL.	
	Examiner Charanjit S. Aulakh	Art Unit 1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 July 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-52 is/are pending in the application.
- 4a) Of the above claim(s) 3 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 2 and 4-52 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input checked="" type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date: <u>8/4/06</u> . |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date <u>3/15, 6/14, 6/8</u> . | 6) <input type="checkbox"/> Other: _____. |

DETAILED ACTION

1. According to paper filed on July 17, 2006, the applicants elected group I with traverse for further prosecution in response to restriction requirement. However, during a telephone conversation with the applicant's attorney on Aug. 4, 2006, it was found that there was a confusion regarding the value of variable Q. The examiner wrote the original restriction requirement based on the assumption that when Q represented –N(R)-(C1-C3)alkylene, –N(R)- group was substituted with C1-C3 alkylene group and therefore, Q-containing ring was always a 5-membered ring containing 1N atom. However, during a telephonic conversation with the applicant's attorney on Aug. 4, 2006, the attorney mentioned that when Q represented N(R)-(C1-C3)alkylene, alkylene group represents part of the ring and therefore, Q-containing ring can be a 6, 7 or 8-membered ring containing 1 N atom. Due to this confusion, an agreement was reached to rewrite the restriction requirement as following :

Election/Restrictions

2. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-5 and 35-52, drawn to compounds of formula (I) where Q represents –N(R)-, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 548, subclass 421.
- II. Claims 1, 2 and 4-52, drawn to compounds of formula (I) where Q represents –N(R)-(C1) alkylene, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 546, subclass 70.

III. Claims 1, 2, 4, 5 and 35-52, drawn to compounds of formula (I) where Q represents $-N(R)-(C_2-C_3)$ alkylene, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 540, subclass 476.

3. The inventions I, II and III as defined above are patentably distinct, each from the other since they are structurally so divergent that a reference showing compounds of invention I would not render compounds of inventions II or III prima facie obvious. Search required for e.g ; compounds of invention I in class 548 is not the same search required for e.g ; compounds of invention II in class 546 and therefore, constitutes a burdensome search.

4. During a telephone conversation with the applicant's attorney, Mr. Roger Rich on Aug. 4, 2006, a provisional election was made with traverse to prosecute the invention of group II, claims 1, 2 and 4-52. Affirmation of this election must be made by applicant in replying to this Office action. Claim 3 is withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Claim Rejections - 35 USC § 112

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1625

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 6-52 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The following eight different factors (see *Ex parte Foreman*, 230 USPQ at 547; *Wands, In re*, 858.F. 2d 731, 8 USPQ 2d 1400, Fed. Cir. 1988) must be considered in order for the specification to be enabling for what is being claimed:

Quantity of experimentation necessary, the amount of direction or guidance provided, presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability or unpredictability and the breadth of claims. In the instant case, the specification is not enabling based on at least four of the above mentioned eight different factors such as quantity of experimentation necessary, the amount of direction or guidance provided, presence of working examples, the state of the prior art, unpredictability and the breadth of claims.

In regard to making hydrates, solvates and prodrugs of instant compounds of formula II (claims 6-52) , there is no teaching or guidance present in the specification for preparing specific hydrates, solvates and prodrugs. There is not even a single example present in the specification for preparing hydrates, solvates and prodrugs of instant compounds of formula II. There is lot of unpredictability regarding stability of hydrates and solvates of compounds in the art. Similarly, there is lot of unpredictability regarding

Art Unit: 1625

effectiveness of various forms of prodrugs following their in vivo administration. The instant compounds of formula II encompasses hundreds of thousands of compounds based on the values of variables R1, R2, R", L1, L2, X, Y, Z and n and therefore, in absence of such teachings, guidance, presence of working examples and unpredictability, it would require undue experimentation to select specific hydrates, solvates and prodrugs which will be stable and also effective following their in vivo administration.

In regard to using instant compounds of formula II (see claims 35-52) for treating various disease conditions, the specification mentions in example 80 on pages 92 and 93 that modulatory activity of instant compounds can be assessed using the in vitro and in vivo assay methods described above and furthermore, mentions that exemplary compounds demonstrated MCHR1 modulatory activity. However, there is no teaching in the specification whether the compounds are agonists or antagonists at MCHR1 receptors. The utility of instant compounds will be different based on agonist versus antagonist activity of instant compounds at MCHR1 receptors. There is no teaching or direction present regarding specific in vitro or in vivo assays for evaluating agonist versus antagonist activity of instant compounds at MCHR1 receptors. There are no working examples present showing efficacy of instant compounds in known in vivo or in vitro models of any disease condition including obesity, eating disorders, anxiety disorders and mood disorders. There is no teaching either in the specification or in the prior art regarding well known utility of structurally closely related compounds for treating any disease condition including obesity, eating disorders, anxiety disorders and

mood disorders. The instant compounds of formula II encompasses hundreds of thousands of compounds based on the values of variables R1, R2, R", L1, L2, X, Y, Z and n and therefore, in absence of such teachings, guidance, presence of working examples and the state of the prior art, it would require undue experimentation to evaluate agonist versus antagonist activity at MCHR1 receptors and to demonstrate the efficacy of instant compounds in known in vitro or in vivo models of various disease conditions including obesity, eating disorders, anxiety disorders and mood disorders and hence their utility for treating these disease conditions.

8. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

9. Claims 1, 2 and 4-52 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In independent claim 1, variable R1 is defined but is not present in formula (I). It appears that (Ar) group should be substituted with (R1)n and not (R)n. An appropriate correction is required.

In independent claim 1 (lines 42-46) and claim 6 (lines 91-95), variables R5-R18 are mentioned to contain R groups. However, according to the definition of these variables, these variables do not contain R group at all. The only variable which contains R group is variable Q in formula (I) in claim 1. An appropriate correction is required.

In independent claim 6, the terms --- hydrates, solvates and prodrugs --- are indefinite since specific hydrates, solvates and prodrugs are not defined.

In claims 41 and 50, the term --modulating -- is indefinite since it is not clear whether the MCHR is activated , inhibited or unchanged?

In claim 45, specific disorders or conditions mediated by MCHR are not defined.

Claim 15 recites the limitation "p is 1, 2 or 3" in claim 13. There is insufficient antecedent basis for this limitation in the claim.

10. Claims 1, 2, 4, 5 and 35-52 are objected for containing non-elected subject matter.

Allowable Subject Matter

11. The following is a statement of reasons for the indication of allowable subject matter:

The instant compounds directed to the elected subject matter are allowable over the prior art since they are neither disclosed nor obvious over the prior art. In the prior art, Chen (U.S. Patent 6,858,619) discloses fused heterocyclic compounds which are closely related to the instant compounds. However, the closely related compound (see example 10 in column 31) differs from the instant compounds in lacking instant variable Z and furthermore, there is no teaching or motivation in the prior art to modify the compounds of Chen to prepare the instant compounds.


12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charanjit S. Aulakh whose telephone number is (571)272-0678. The examiner can normally be reached on Monday through Friday, 8:30 A.M. to 5:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thomas McKenzie can be reached on (571)272-0670. The fax phone

Art Unit: 1625

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


Charanjit S. Aulakh
Primary Examiner
Art Unit 1625

Interview Summary	Application No.	Applicant(s)	
	10/705,173	CHEN ET AL.	
	Examiner	Art Unit	
	Charanjit S. Aulakh	1625	

All participants (applicant, applicant's representative, PTO personnel):

(1) Charanjit S. Aulakh. (3)_____.

(2) Roger Rich. (4)_____.

Date of Interview: 04 August 2006.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.
If Yes, brief description: _____.

Claim(s) discussed: _____.

Identification of prior art discussed: _____.

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☐ N/A.


Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: A telephone call was made to the applicant's attorney to clarify the elected group in response to restriction requirement. Following conversation with the applicant's attorney, an agreement was reached to rewrite restriction requirement based on the value of variable Q. During this conversation, the applicants elected group II (Q is -N(R)-(C1)-alkylene with traverse.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required


LIST OF REFERENCES CITED BY APPLICANT
 (Use several sheets if necessary)

ATTY DOCKET NO.

11134-013-999

APPLICATION NO

10/705,173

APPLICANT

Chen *et al.*

FILING DATE

November 6, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
CA	C01	Supplementary European Search Report EP 02 73 4135	4/4/05	EPO		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C02	Sainsbury, Malcom, 1977 "The Synthesis of 6H-Pyrido[4,3-b]Carbazoles" <i>Synthesis</i> , 7: 437-448.
-----	--

EXAMINER	AULAKH	DATE CONSIDERED	8/4/06
----------	--------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.
11134-013-999

APPLICATION NO
10/705,173

APPLICANT
Chen *et al.*

FILING DATE
November 6, 2003

GROUP
1614


U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CA	B01	5,441,956	8/15/95	Vecchiotti <i>et al.</i>	1		
CA	B02	5,457,208	10/10/95	Portoghese <i>et al.</i>			
CA	B03	20030023085	1/30/03	Chen <i>et al.</i>			
CA	B04	20030176694	9/18/03	Chen <i>et al.</i>			
CA	B05	20030199549	10/23/03	Burnett <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
CA	B06	WO91/07966	6/13/91	PCT				
CA	B07	WO94/07896	4/14/94	PCT				
CA	B08	WO95/13071	5/18/95	PCT				
CA	B09	WO96/23793	8/08/96	PCT				
CA	B10	WO98/31684	7/23/98	PCT				
CA	B11	WO00/21577	4/20/00	PCT				
CA	B12	WO00/49046	8/24/00	PCT				
CA	B13	WO01/21169	3/29/01	PCT				
CA	B14	WO01/87834	11/22/01	PCT				
CA	B15	WO02/002744	1/10/02	PCT				
CA	B16	WO02/03070	1/10/02	PCT				
CA	B17	WO02/04433	1/17/02	PCT				
CA	B18	WO02/06245	1/24/02	PCT				
CA	B19	WO02/032897	4/25/02	PCT				
CA	B20	WO02/051809	7/04/02	PCT				
CA	B21	WO02/057233	7/25/02	PCT				
CA	B22	WO02/076929	10/03/02	PCT				
CA	B23	WO02/076947	10/03/02	PCT				
CA	B24	WO02/083134	10/24/02	PCT				
CA	B25	WO02089729	11/14/02	PCT				
CA	B26	WO02/094799	11/28/02	PCT				
CA	B27	WO03/060475	07/24/03	PCT				
CA	B28	JP 4-368384	12/21/92	JP				
CA	B29	JP 2001-226269	8/21/01	JP				
CA	B30	International Search Report PCT/US03/35543	04/15/04	PCT				

CAJD: 502915.1



OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)		
CA	B31	Aceto, MD et al., "Dependence studies of new compounds in the Rhesus monkey, rat and mouse", (1997) Department of Pharmacology and Toxicology, Medical College of Virginia Commonwealth University, pp 363-407.
CA	B32	Bergman et al., 1980 "ACTA Chemica Scandinavica, Series B; Organic Chemistry and Biochemistry B34(10):763-66.
CA	B33	Blechert, S. et al., "Domino reactions - New concepts in the synthesis of indole alkaloids and other polycyclic indole derivatives", (1995) Institut Für Organische Chemie, Sekr. C3, Technische Universität Berlin, Straße des 17 Juni 135, D-10623 Berlin, Germany pp 592-604.
CA	B34	Boutin et al., (2002) "Melanin-Concentrating Hormone and its Receptors: State of the Art," Can. J. of Physio. and Pharmacol. 80: 388-395.
CA	B35	Chambers et al., "Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1" <i>Nature</i> , (1999) 400:261-65
CA	B36	Fujii, H. et al., "A novel abnormal rearrangement in the fishcer indole synthesis", (1997) <i>Heterocycles</i> 45:2109-2112.
CA	B37	Gouyette, A. et al., "Synthesis, DNA intercalation and antitumor activity of 9-hydroxy-11-demethylellipticine and some derivatives. Comparison with the corresponding ellipticines", (1980) <i>Euro. J. Med. Chem.</i> 15:503-510.
CA	B38	Guillonneau, C. et al., "Synthesis of 9-O-substituted derivatives of 9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxylic acid (2-(dimethylamino)ethyl)amide and their 10- and 11-methyl analogues with improved antitumor activity", (1990) <i>J. Med. Chem.</i> 42:2191-2203.
CA	B39	Ishikura et al., "A Novel Entry to Pyrido [4,3-b] Carbazole: An Efficient Synthesis of Ellipticine", Chemical Abstract, Vol. 132, Abstract 237230, 2000
CA	B40	Jones, RM et al., "5'-Guanidinonaltrindole, a highly selective and potent k-opioid receptor atagonist" (2000) <i>Euro. J. Med. Chem.</i> 39:49-52.
CA	B41	Langlois et al., (1975) <i>Tetrahedron Letters</i> 11: 955-958.
CA	B42	Lipkowski, AW et al., "Benzomorphan alkaloids: natural peptidomimetics of opioid peptide pharmacophores", (1995) <i>Letters in Peptide Science</i> , 2:177-181.
CA	B43	Olmsted, SL et al., "A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic κ address element to the δ antagonist, naltrindole: 5'-[(N ² -alkylamidino)methyl]naltrindole derivatives as a novel class of κ opioid receptor antagonists" (1993) <i>J. Med. Chem.</i> 36:179-180.
CA	B44	Portoghese, PS et al., "Naltrindole 5'-isothiocyanate: a nonequilibrium, highly selective δ opioid receptor antagonist" (1990) <i>J. Med. Chem.</i> 33:1547-1548.
CA	B45	Portoghese, PS et al., "Design of peptidomimetic δ opioid receptor antagonists using the message-address concept" (1990) <i>J. Med. Chem.</i> 33:1714-1720.
CA	B46	Portoghese, PS et al., "Application of the message-address concept in the design of highly potent and selective non-peptide δ opioid receptor antagonists", (1988) <i>J. Med. Chem.</i> 31:281-282.
CA	B47	Portoghese, PS et al., "7'-substituted amino acid conjugates of naltrindole. Hydrophilic groups as determinants of selective antagonism of δ opioid receptor-mediated antinociception in mice." (1995) <i>J. Med. Chem.</i> 38:402-407.
CA	B48	Rastogi, et al. 1987 "Synthesis, Neuroleptic & Antiinflammatory Activities of 4a, 11a-cis-&trans-2-{ γ -(p-Fluorobenzoyl)propyl}-1,2,3,4,4a,5,11,11 a-octahydro-6H-pyrido[4,3-b]carbazoles & Related Derivatives," <i>India Journal of Chemistry</i> 26B: 335-340.
CA	B49	Série G "Chimie Organique. - Une nouvelle synthèse du système 6 H-pyrido-(4.3b) carbaxolique", (1972) <i>C.R. Acad. Sc. Paris</i> , t. 274:1948-1949.
CA	B50	Stevens, WC et al., "Potent and selective indolomorphinan antagonists of the kappa-opioid receptor", (2000) <i>J. Med. Chem.</i> 43:2759-2769.

EXAMINER


AULAKH

DATE CONSIDERED

8/4/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	11134-013-999	10/705,173
	APPLICANT Chen et al.	
	FILING DATE	GROUP
	November 6, 2003	To be Assigned



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CA	A01	4,115,538	9/19/78	Satoh et al.			
CA	A02	5,436,128	7/25/95	Harpold et al.			
CA	A03	5,049,655	9/17/91	Vaughan et al.			
CA	A04	5,272,146	12/21/93	Haugwitz et al.			
CA	A05	5,449,766	9/12/95	Vaughan et al.			
CA	A06	5,530,095	6/25/96	Vaughan et al.			
CA	A07	5,849,708	12/15/98	Maratos-Flier			
CA	A08	6,033,872	3/7/00	Bergsma et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
CA	A09	EP 0 257 701	8/14/87	EPO				
CA	A10	WO99/28492	12/2/98	PCT				
CA	A11	WO99/64002	6/10/99	PCT				
CA	A12	WO00/15793	9/17/99	PCT				
CA	A13	WO00/22129	10/12/99	PCT				
CA	A14	WO00/39279	12/30/99	PCT				
CA	A15	WO00/40725	12/27/99	PCT				
CA	A16	WO00/49046	2/18/00	PCT				
CA	A17	WO00/49170	1/20/00	PCT				
CA	A18	WO00/70347	11/23/00	PCT				
CA	A19	WO00/75166	6/6/00	PCT				
CA	A20	WO01/05947	7/10/00	PCT				
CA	A21	WO01/07606	7/27/00	PCT				
CA	A22	WO01/07611	7/21/00	PCT				
CA	A23	WO01/21577	9/19/00	PCT				
CA	A24	WO01/36479	11/14/00	PCT				
CA	A25	WO01/68706	3/14/01	PCT				
CA	A26	WO01/70975	3/23/01	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	A27	Berridge, <i>et al.</i> "Inositol Triphosphate, a Novel Second Messenger In Cellular Signal Transduction", Nature (1984) 312:315-321.
CA	A28	Chambers, <i>et al.</i> "Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1", Nature (1999) 400: 261-265.
CA	A29	Felley-Bosco, <i>et al.</i> "Constitutive Expression of Inducible Nitric Oxide Synthase in Human Brochial Epithelial Cells Induces c-fos and Stimulates the cGMP Pathway", Am J. Respir Cell. Mol. Biol. (1994) 11: 159-164.

CAJD: 500759.1

CA	A30	Gonzalez, <i>et al.</i> , "alpha-Melanocyte-stimulating hormone (alpha-MSH) and melanin-concentrating hormone (MCH) modify monoaminergic levels in the preoptic area of the rat" <i>Peptides</i> (1997) 18:387-392.
CA	A31	Gonzalez, <i>et al.</i> , "Behavioral Effects of α -MSH and MCH After Central Administration in the Female Rat" <i>Peptides</i> (1996) 17(1):171-177.
CA	A32	Monzon, <i>et al.</i> , "Response to Novelty After I.C.V. Injection of Melanin-Concentrating Hormone (MCH) in Rats" <i>Physiol. Behav.</i> (1999) 67(5):813-817.
CA	A33	Offerman, <i>et al.</i> , " $G\alpha_{15}$ and $G\alpha_{16}$ Couple A Wide Variety of Receptors to Phospholipase C", <i>The J. of Biological Chemistry</i> (1995), 270(25) pgs. 15175-15180.
CA	A34	Rai, <i>et al.</i> , "Synthesis, Physicochemical Properties, and Evaluation of N-Substituted-2-Alkyl-3-Hydroxy-4(1H)-Pyridones" <i>J. Med. Chem.</i> (1998) 41:3347-3359.
CA	A35	Saito, <i>et al.</i> , "Molecular characterization of the melanin-concentrating-hormone receptor", <i>Nature</i> (1999) 400: 265-269.
CA	A36	Saito, <i>et al.</i> , "Melanin-concentrating hormone receptor: an orphan receptor fits the key" <i>Trends Endocrinol. Metab.</i> (2000) 11(8): 299-303.
CA	A37	Seyferth, <i>et al.</i> , "Some Reactions of Dimethylphosphono-Substituted Diazoalkanes. $(MeO)_2P(O)CR$ Transfer to Olefins and 1,3-Dipolar Additions of $(MeO)_2P(O)C(N_2)R^1$ ", <i>J. Org. Chem.</i> (1971) 36(10): 1379-1386.
CA	A38	Shimada, <i>et al.</i> , "Mice Lacking melanin-concentrating hormone are Hypophagic and Lean", <i>Nature</i> (1998) 396: 670-674.
CA	A39	Wilkie, <i>et al.</i> , "Characterization of G-Protein α Subunits in the G_q Class: Expression in Murine Tissues and In Stromal and Hematopoietic Cell Lines", <i>Proc. Natl. Acad. Sci. USA</i> (1991) 88: pgs 10049-10053..

EXAMINER	AULAKH	DATE CONSIDERED	8/4/06
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			



Notice of References Cited	Application/Control No. 10/705,173	Applicant(s)/Patent Under Reexamination CHEN ET AL.	
	Examiner Charanjit S. Aulakh	Art Unit 1625	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-6,858,619	02-2005	Chen et al.	514/285
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent and Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.